Search results
Added:
5 months ago
Source:
Radcliffe Cardiology
New analyses from the ATTRibute-CM trial show that the transthyretin (TTR) stabiliser acoramidis provides consistent clinical benefits in patients with both wild-type (ATTRwt-CM) and variant (ATTRv-CM) transthyretin amyloid cardiomyopathy.1 The findings include data from the main 30-month trial and its ongoing 42-month open-label extension (OLE).Acoramidis is an orally administered, small…
View more
Added:
7 months ago
Source:
Radcliffe Cardiology
Two phase 3 trials presented at the European Society of Cardiology Congress 2025 have provided new insights into the role of myosin inhibitors for hypertrophic cardiomyopathy (HCM), with one trial demonstrating superiority over standard care in obstructive HCM and another failing to meet its primary endpoints in the non-obstructive form of the disease.¹˒²The MAPLE-HCM trial found that the cardiac…
View more
Added:
1 month ago
Source:
Radcliffe Cardiology
Therapies for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including transthyretin (TTR) stabilisers and silencers, have demonstrated a mortality benefit in randomised trials. However, the timing of this benefit has been a subject of debate. A new analysis of three major outcomes trials has evaluated this time course, revealing a consistent pattern across different treatments…
View more
Added:
1 month ago
Source:
Radcliffe Cardiology
A new study has revealed significant delays in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) following an initial diagnosis of heart failure (HF), with the median time to diagnosis exceeding one year.¹ Timely identification of ATTR-CM is critical to reduce morbidity and mortality, as effective treatments are available.²MethodologyThis retrospective cohort study analysed data…
View more
Added:
2 years ago
Source:
Radcliffe Cardiology
AUTHOR: Greg GuilloryTwo late-breaking clinical trials addressing cardiovascular outcomes in patients with diabetes were presented this week at the American College of Cardiology meeting in Atlanta, USA. One of these trials looked at the effects of the hyperactivation of the polyol pathway on diabetic cardiomyopathy (DbCM) and the other the effects of chelation therapy in patients with diabetes…
View more
Added:
9 months ago
Source:
ESC Congress 2025 Scientific Programme
Ten hot line sessions have been announced for ESC Congress 2025.The congress is set to take place from the 29th August to 1st September at IFEMA - Fiera de Madrid.Access the full programme here.Hot Line 1Friday 29th August, 11:00am – 12:00pm (CEST)POTCAST – a Randomized Controlled Trial of Arrhythmia prevention using targeted plasma potassium levels in ICD Patients – Presented by Christian…
View more
Added:
3 months ago
Source:
Radcliffe Cardiology
A new study published in JACC has evaluated the prevalence and prognostic significance of secondary tricuspid regurgitation (STR) across the spectrum of heart failure with preserved ejection fraction (HFpEF), finding that its presence is strongly associated with pulmonary vascular disease (PVD) and that different mechanisms of STR carry distinct prognoses.¹˒²This observational study analysed data…
View more
Added:
1 year ago
Source:
Radcliffe CVRM
A recent study published in Circulation: Heart Failure1 has found that multimorbidity, the presence of two or more chronic health conditions, substantially increases the risk of mortality in patients with heart failure who have mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF).The study analyzed data from two major heart failure trials: TOPCAT-Americas (Treatment of Preserved Cardiac…
View more
Added:
6 months ago
Source:
Radcliffe Cardiology
AUTHOR: Yazmin SadikNew findings from the DIGIT-HF trial indicate that adding low-dose digitoxin to guideline-directed medical therapy (GDMT) can reduce the risk of hospitalisation and all-cause mortality in patients with symptomatic heart failure with reduced ejection fraction (HFrEF).¹The results were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously…
View more
Added:
8 months ago
Source:
Radcliffe Cardiology
With global temperatures rising and heatwaves becoming more frequent and intense, the impact on public health is a growing concern. A new scientific statement from the European Society of Cardiology (ESC) and several of its constituent bodies highlights the significant risk that extreme heat poses to cardiovascular health, particularly for the elderly and individuals with pre-existing…
View more